These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16499662

  • 21. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
    Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, Elenkov I, Yankova M.
    Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
    [Abstract] [Full Text] [Related]

  • 22. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F, Mezzaroma I.
    AIDS Rev; 2006 Jul; 8(2):88-97. PubMed ID: 16848276
    [Abstract] [Full Text] [Related]

  • 23. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.
    AIDS; 2006 Aug 01; 20(12):1613-9. PubMed ID: 16868442
    [Abstract] [Full Text] [Related]

  • 25. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C, Lee S, Wong Kh, Cheng L, Lam M.
    HIV Med; 2007 Apr 01; 8(3):181-5. PubMed ID: 17461862
    [Abstract] [Full Text] [Related]

  • 26. Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy.
    Boulassel MR, Smith GH, Edwardes MD, Young M, Klein M, Gilmore N, Macleod J, Leblanc R, René P, Allan J, Lalonde RG, Routy JP.
    HIV Med; 2005 Jul 01; 6(4):268-77. PubMed ID: 16011532
    [Abstract] [Full Text] [Related]

  • 27. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Jul 01; 12(6):889-97. PubMed ID: 17926643
    [Abstract] [Full Text] [Related]

  • 28. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, Wynne SM, Davey RT, Lane HC, Sereti I.
    AIDS; 2006 Feb 14; 20(3):361-9. PubMed ID: 16439869
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 14; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 31. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, French MA.
    AIDS; 2007 Jul 31; 21(12):1525-34. PubMed ID: 17630546
    [Abstract] [Full Text] [Related]

  • 32. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, Molteni C, Trabattoni D, Fossati S, Clerici M, Galli M, Moroni M, Franzetti F, Gori A.
    J Infect Dis; 2002 Sep 01; 186(5):606-16. PubMed ID: 12195347
    [Abstract] [Full Text] [Related]

  • 33. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B, TIBET Study Group.
    AIDS; 2007 Jan 11; 21(2):169-78. PubMed ID: 17197807
    [Abstract] [Full Text] [Related]

  • 34. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
    Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, Viard JP, Weiss L, Netzer E, Delfraissy JF, Aboulker JP, Lévy Y.
    AIDS; 2007 Sep 12; 21(14):1887-97. PubMed ID: 17721096
    [Abstract] [Full Text] [Related]

  • 35. Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.
    Forcina G, D'Ettorre G, Mastroianni CM, Carnevalini M, Scorzolini L, Ceccarelli G, D'Agostino C, Lichtner M, Massetti AP, Vullo V.
    Cytokine; 2004 Mar 21; 25(6):283-90. PubMed ID: 15036244
    [Abstract] [Full Text] [Related]

  • 36. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M, Keane N, McKinnon E, Phung S, Price P.
    HIV Med; 2007 Apr 21; 8(3):148-55. PubMed ID: 17461858
    [Abstract] [Full Text] [Related]

  • 37. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI.
    J Med Virol; 2009 Mar 21; 81(3):441-5. PubMed ID: 19152397
    [Abstract] [Full Text] [Related]

  • 38. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX.
    Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013
    [Abstract] [Full Text] [Related]

  • 39. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L, Ryder LP, Albrecht-Beste E, Jensen FK, Nielsen SD.
    Scand J Immunol; 2009 Dec 20; 70(6):608-13. PubMed ID: 19906203
    [Abstract] [Full Text] [Related]

  • 40. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
    Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA.
    HIV Clin Trials; 2000 Dec 20; 1(3):1-15. PubMed ID: 11590500
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.